Cullinan Oncology LLC (CGEM) stock has reached a new 52-week low, trading at $9.48 USD, signaling a period of significant ...

CEO, Timothy Whitten. Alongside its growing pipeline of orally administered oncology drugs, the US subsidiary of Japan’s Taiho Pharmaceutical Co., Ltd. is looking to expand its product portfolio ...

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Cullinan Management (CGEM – Research Report). The associated price ...

Taiho Pharmaceutical and Taiho Oncology reported that a Phase 1/2 study of the drug zipalertinib met its primary endpoint of overall response rate in a study of EGFR lung cancer patients. The drug was ...

14, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today that oral decitabine and ...

PRINCETON, N.J., Jan. 24, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid ...